title: Bradykinin receptors as a therapeutic target.
abstract: Biologically-active kinins, including bradykinin (BK) and Lys(0)-BK (kallidin), are short-lived peptide mediators predominantly generated by the enzymatic action of kallikreins on kininogen precursors. A diverse spectrum of physiological and pathological actions attributed to local kinin production is a consequence of the activation of G-protein-coupled receptors (GPCRs). Currently, two major subtypes of kinin receptor, designated B(1) and B(2), are recognised, although there is much evidence for pharmacological heterogeneity, particularly within the B(2) receptors. Considering these facts and the widespread distribution of kinin receptors in many human tissues, it is no surprise that the therapeutic potential of kinins and kinin receptor antagonists remains the focus of numerous investigations. Studies in animals and animal tissues, instrumental in elucidating the biological roles of kinins, are well-documented in numerous excellent reviews. Unfortunately, and despite the enormous potential illustrated by animal studies, attempts to develop kinin analogues as therapeutic agents to combat human disease have largely proven disappointing. Consequently, this review selectively focuses upon studies that are directly relevant to the targeting of human BK receptors as a therapeutic intervention. In addition to providing a succinct review of well-documented pathological conditions to which kinin receptors contribute, the authors have also included more recent data that illustrate new avenues for the therapeutic application of kinin analogues.
authors.affiliation: Molecular Pharmacology Group, School of Applied Sciences, University of Wolverhampton,Wulfruna Street, Wolverhampton WV1 1SB, UK. J.Howl@wlv.ac.uk
authors.forename: John
authors.initials: J
authors.lastname: Howl
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Payne
mesh_terms: D000700:Analgesics / Q000494:pharmacology* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001920:Bradykinin / Q000502:physiology; D002319:Cardiovascular System / Q000503:physiopathology; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D007610:Kallikreins / Q000502:physiology; D007704:Kininogens / Q000502:physiology; D007705:Kinins / Q000502:physiology; D010146:Pain / Q000188:drug therapy*; D018002:Receptors, Bradykinin / Q000187:drug effects* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents; D007704:Kininogens; D007705:Kinins; D018002:Receptors, Bradykinin; D007610:Kallikreins; D001920:Bradykinin